Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-1.42Last Year’s EPS
-1.31Same Quarter Last Year
Strong Buy
Based on 20 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -5.42%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments, such as early trial enrollment completion and strong financial positioning, countered by delays in drug approval and increased expenses. The sentiment is balanced with notable achievements and challenges.Company Guidance
During the first quarter of 2025, Cytokinetics provided detailed guidance on several key metrics across its business operations. The company's financial position remained strong, with approximately $1.1 billion in cash, cash equivalents, and investments as of the end of the quarter. Research and development expenses increased to $99.8 million from $81.6 million in 2024, reflecting advancements in clinical trials and personnel costs. General and administrative expenses rose to $57.4 million, driven by investments in commercial readiness. The net loss for the quarter was $161.4 million, or $1.36 per share. For the full year 2025, the company maintained its financial guidance, expecting GAAP operating expenses between $670 million and $710 million, with a stock-based compensation range of $110 million to $120 million. Excluding stock-based compensation, expenses are projected between $550 million and $600 million. These figures incorporate the impact of a PDUFA date extension for aficamten, which affects the timing of launch expenses and increases R&D costs due to accelerated enrollment in the ACACIA trial.Strong Start to Fiscal Year 2025
Cytokinetics reported a robust beginning to the fiscal year with significant progress across their projects, setting a solid foundation for future growth.
ACACIA-HCM Enrollment Completed Early
The pivotal Phase III clinical trial of aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM) completed enrollment six months ahead of schedule, enabling top-line results in the first half of 2026.
High Interest in Salesforce Recruitment
The company received several thousand applications for sales positions, with a high level of interest and many candidates possessing cardiology experience.
Financial Position
Cytokinetics ended the first quarter with approximately $1.1 billion in cash, cash equivalents, and investments, providing a strong financial base for future operations.
Partnership with Sanofi in China
The collaboration with Sanofi is progressing to support the NDA review of aficamten with the NMPA, indicating potential for growth in the Chinese market.
---
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $33.97 | $33.04 | -2.74% |
Feb 27, 2025 | $47.45 | $46.00 | -3.06% |
Nov 06, 2024 | $55.50 | $55.84 | +0.61% |
Aug 08, 2024 | $54.00 | $55.79 | +3.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2025 (Q2) is -1.42.
---